Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Durability of immune responses to mRNA booster vaccination against COVID-19
Prabhu S. Arunachalam, … , Mehul S. Suthar, Bali Pulendran
Prabhu S. Arunachalam, … , Mehul S. Suthar, Bali Pulendran
Published March 23, 2023
Citation Information: J Clin Invest. 2023;133(10):e167955. https://doi.org/10.1172/JCI167955.
View: Text | PDF
Clinical Research and Public Health Article has an altmetric score of 5

Durability of immune responses to mRNA booster vaccination against COVID-19

  • Text
  • PDF
Abstract

Background Maintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown.Methods We measured antibody responses in 55 healthy adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of the antibody titers. We also measured memory B and T cell responses in a subset of 28 participants. In 13 volunteers who received a second booster vaccine, we measured serum antibody titers and memory B and T cell responses.Results The booster (third immunization) dose at 6 to 10 months increased the half-life of the serum–neutralizing antibody (nAb) titers to 76 days from 56 to 66 days after the primary 2-dose vaccination. A second booster dose (fourth immunization) a year after the primary vaccination further increased the half-life to 88 days. However, despite this modestly improved durability in nAb responses against the ancestral (WA.1) strain, there was a loss of neutralization capacity against the Omicron subvariants BA.2.75.2, BQ.1.1, and XBB.1.5 (48-, 71-, and 66-fold drop in titers, respectively, relative to the WA.1 strain). Although only 45% to 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (third dose), the response declined to below the detection limit in almost all individuals by 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months.Conclusion The durability of serum antibody responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.

Authors

Prabhu S. Arunachalam, Lilin Lai, Hady Samaha, Yupeng Feng, Mengyun Hu, Harold Sai-yin Hui, Bushra Wali, Madison Ellis, Meredith E. Davis-Gardner, Christopher Huerta, Kareem Bechnak, Sarah Bechnak, Matthew Lee, Matthew B. Litvack, Cecilia Losada, Alba Grifoni, Alessandro Sette, Veronika I. Zarnitsyna, Nadine Rouphael, Mehul S. Suthar, Bali Pulendran

×

Total citations by year

Year: 2025 2024 2023 Total
Citations: 14 20 9 43
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (44)

Title and authors Publication Year
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Liu J, Wang L, Kurtesi A, Budylowski P, Potts KG, Menon H, Tan Y, Samaan P, Liu X, Wang Y, Hu Q, Samson R, Qi F, Evseev D, John C, Ellestad KK, Fan Y, Budiman F, Tohan ER, Udayakumar S, Yang J, Marcusson EG, Gingras AC, Mahoney DJ, Ostrowski MA, Martin-Orozco N
NPJ Vaccines 2025
Rethinking Optimal Immunogens to Face SARS‐CoV‐2 Evolution Through Vaccination
Blanco J, Trinité B, Puig\u2010Barberà J
Influenza and Other Respiratory Viruses 2025
Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort
Sheehan J, Trauth AJ, Hagensee ME, Ramsay AJ
Pathogens 2025
Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
da Silva Antunes R, Fajardo-Rosas V, Yu ED, Gálvez RI, Abawi A, Alexandar Escarrega E, Martínez-Pérez A, Johansson E, Goodwin B, Frazier A, Dan JM, Crotty S, Seumois G, Weiskopf D, Vijayanand P, Sette A
bioRxiv 2025
Evaluation of COVID-19 Booster Vaccine Effectiveness
Qu B, Zhang D
Viruses 2025
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue Y, Hou X, Zhong Y, Zhang Y, Du S, Kang DD, Wang L, Wang C, Li H, Wang S, Liu Z, Tian M, Guo K, Cao D, Deng B, McComb DW, Purisic E, Dai J, Hamon P, Brown BD, Tsankova NM, Merad M, Irvine DJ, Weiss R, Dong Y
Nature Communications 2025
Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine
Wang X, Yang X, Zhang X, Yan H, Jin J, Ma Z, Duan J, Zhang G, Huang T, Li Y, Wu H, Zhang T, Zhu A, Jin C, Song X, Su B
Frontiers in Immunology 2025
Intestinal Microbiota and Vaccinations: A Systematic Review of the Literature
Loddo F, Laganà P, Rizzo CE, Calderone SM, Romeo B, Venuto R, Maisano D, Fedele F, Squeri R, Nicita A, Nirta A, Genovese G, Bartucciotto L, Genovese C
Vaccines 2025
Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques
Karaliota S, Moussa M, Rosati M, Devasundaram S, Sengupta S, Goldfarbmuren KC, Burns R, Bear J, Stellas D, Urban EA, Deleage C, Khandhar AP, Erasmus J, Berglund P, Reed SG, Pavlakis GN, Felber BK
iScience 2025
Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale
Edeling MA, Earnest L, Carrera Montoya J, Yap AH, Mumford J, Roberts J, Wong CY, Hans D, Grima J, Bisset N, Bodle J, Rockman S, Torresi J
Biotechnology and Bioengineering 2025
Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4
Zelkoski AE, Lu Z, Sukumar G, Dalgard C, Said H, Alameh MG, Mitre E, Malloy AM
NPJ Vaccines 2025
Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients
Hu M, Oliveira AP, Fang Z, Feng Y, Miranda M, Kowli S, Arunachalam PS, Vasudevan G, Hui HS, Grifoni A, Sette A, Litvack M, Rouphael N, Suthar MS, Ji X, Maecker HT, Hagan T, Dhillon G, Nicolls MR, Pulendran B
Cell Reports Medicine 2025
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study
López MJ, Vazquez MD, Alvarez-Mon M, Arribas JR, Arana-Arri E, Muñoz P, Navarro-Pérez J, Ramos R, Molto J, Otero-Romero S, Aurrecoechea E, Pomarol R, Bernad L, Esteban I, Pérez-Caballero R, Plana M, Prado JG, Soriano Á
Human Vaccines & Immunotherapeutics 2025
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year
Mcconney CS, Kenney D, Ennis CS, Smith-Mahoney EL, Ayuso MJ, Zhong J, Douam F, Sagar M, Snyder-Cappione JE
Viruses 2025
Hybrid Immunity from Gam-COVID-Vac Vaccination and Natural SARS-CoV-2 Infection Confers Broader Neutralizing Activity against Omicron Lineage VOCs Than Revaccination or Reinfection.
Kulemzin SV, Guselnikov SV, Nekrasov BG, Molodykh SV, Kuvshinova IN, Murasheva SV, Belovezhets TN, Gorchakov AA, Chikaev AN, Chikaev NA, Volkova OY, Yurina AA, Najakshin AM, Taranin AV
Human vaccines 2024
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
Ziemssen T, Groth M, Ettle B, Bopp T
Human Vaccines & Immunotherapeutics 2024
Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection.
Bates JT, Lirette ST, Farmer AP, Bierdeman MA, Seyfarth KB, Ederer DR, Montgomery DD, Burnett GC, Pham AT, Marshall GD
Human Vaccines & Immunotherapeutics 2024
Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
Martín Pérez C, Aguilar R, Jiménez A, Salmerón G, Canyelles M, Rubio R, Vidal M, Cuamba I, Barrios D, Díaz N, Santano R, Serra P, Santamaria P, Izquierdo L, Trilla A, Vilella A, Barroso S, Tortajada M, García-Basteiro AL, Moncunill G, Dobaño C
BMC Medicine 2024
Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis
Nham E, Sohn JW, Choi WS, Wie SH, Lee J, Lee JS, Jeong HW, Eom JS, Choi YJ, Seong H, Yoon JG, Noh JY, Song JY, Cheong HJ, Kim WJ
Frontiers in immunology 2024
COVID-19 Vaccination Strategies in the Endemic Period: Lessons from Influenza
Nham E, Noh JY, Park O, Choi WS, Song JY, Cheong HJ, Kim WJ
Human vaccines 2024
Appropriate Sampling and Longer Follow-Up Are Required to Rigorously Evaluate Longevity of Humoral Memory After Vaccination
Ganusov VV
ImmunoHorizons 2024
Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul
Piccoli BC, y Castro TR, Tessele LF, Casarin BC, Seerig AP, Vieira AD, Santos VT, Schwarzbold AV, Trindade PA
Scientific Reports 2024
The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer
Shapiro JR, Corrado M, Perry J, Watts TH, Bolotin S
Human Vaccines & Immunotherapeutics 2024
Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination.
Kim W
Immune network 2024
Durability of immune responses to SARS-CoV-2 infection and vaccination
Suthar MS
Seminars in immunology 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Essink BJ, Shapiro C, Isidro MG, Bradley P, Pragalos A, Bloch M, Santiaguel J, Frias MV, Miyakis S, Alves de Mesquita M, Berrè S, Servais C, Waugh N, Hoffmann C, Baba E, Schönborn-Kellenberger O, Wolz OO, Koch SD, Ganyani T, Boutet P, Mann P, Mueller SO, Ramanathan R, Gaudinski MR, Vanhoutte N
Human Vaccines & Immunotherapeutics 2024
Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant
Laghlali G, Wiest MJ, Karadag D, Warang P, O\u2019Konek JJ, Chang LA, Park SC, Yan V, Farazuddin M, Janczak KW, García-Sastre A, Baker JR Jr, Wong PT, Schotsaert M
Molecular Therapy 2024
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects
Segato I, Mele D, Forlani G, Dalla Gasperina D, Mondelli MU, Varchetta S
Vaccines 2024
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2
Livieratos A, Schiro LE, Gogos C, Akinosoglou K
Vaccines 2024
Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice
Watts JR, Clinton JL, Pollet J, Peng R, Tan J, Ling PD
Vaccines 2024
Transforming Vaccinology
Rappuoli R, Alter G, Pulendran B
Cell 2024
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans
Grigoryan L, Feng Y, Bellusci L, Lai L, Wali B, Ellis M, Yuan M, Arunachalam PS, Hu M, Kowli S, Gupta S, Maysel-Auslender S, Maecker HT, Samaha H, Rouphael N, Wilson IA, Moreno AC, Suthar MS, Khurana S, Pillet S, Charland N, Ward BJ, Pulendran B
Science immunology 2024
Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen
Casmil IC, Bathula NV, Huang C, Wayne CJ, Cairns ES, Friesen JJ, Soriano SK, Liao S, Ho CH, Kong KY, Blakney AK
Molecular Therapy 2024
Neutralizing Activity and T-Cell Responses Against Wild Type SARS-CoV-2 Virus and Omicron BA.5 Variant After Ancestral SARS-CoV-2 Vaccine Booster Dose in PLWH Receiving ART Based on CD4 T-Cell Count
Ha NY, Kim AR, Jeong H, Cheon S, Park CR, Choe JH, Kim HJ, Yoon JW, Kim M, An MY, Jung S, Do HN, Lee J, Kim YS
Journal of Korean Medical Science 2024
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A, Milogiannakis V, Jean T, Esneau C, Silva MR, Ison T, Fichter C, Lopez JA, Chandra D, Naing Z, Caguicla J, Li D, Walker G, Amatayakul-Chantler S, Roth N, Manni S, Hauser T, Barnes T, Condylios A, Yeang M, Wong M, Foster CSP, Sato K, Lee S, Song Y, Mao L, Sigmund A, Phu A, Vande More AM, Hunt S, Douglas M, Caterson I, Britton W, Sandgren K, Bull R, Lloyd A, Triccas J, Tangye S, Bartlett NW, Darley D, Matthews G, Stark DJ, Petoumenos K, Rawlinson WD, Murrell B, Brilot F, Cunningham AL, Kelleher AD, Aggarwal A, Turville SG
EBioMedicine 2023
A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines
Hong M, Lan T, Li Q, Li B, Yuan Y, Xu F, Wang W
Gut microbes 2023
Appropriate sampling and long follow-up are required to rigorously evaluate longevity of humoral memory after vaccination.
Ganusov VV
Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
Kanokudom S, Suntronwong N, Duangchinda T, Wanlapakorn N, Poovorawan Y
Cureus 2023
Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2
Jacobsen H, Sitaras I, Katzmarzyk M, Cobos Jiménez V, Naughton R, Higdon MM, Deloria Knoll M
npj Vaccines 2023
Appropriate sampling and long follow-up are required to rigorously evaluate longevity of humoral memory after Vaccination
Ganusov VV
2023
Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine
Sheehan J, Ardizzone CM, Khanna M, Trauth AJ, Hagensee ME, Ramsay AJ
Human vaccines 2023
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
Jiang H, Jin P, Guo X, Zhu J, Wang X, Wan P, Wan J, Liu J, Li J, Zhu F
Human vaccines 2023
An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants
Liu Z, Li J, Pei S, Lu Y, Li C, Zhu J, Chen R, Wang D, Sun J, Chen K
Frontiers in Cellular and Infection Microbiology 2023
SARS-CoV-2 breakthrough infections following inactivated vaccine vaccination induce few neutralizing antibodies against the currently emerging Omicron XBB variants.
Shen F, Liang C, Yang CX, Lu Y, Li AQ, Duan Y, Zhang M, Tian RR, Dong XQ, Zheng YT, Pang W
Virologica Sinica 2023

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 10 X users
58 readers on Mendeley
See more details